Financial results for the first half of 2009: significant investment in clinical programs and cash position reinforced

• Publication of important clinical data for IPH 1101 and IPH 2101, Innate Pharma’s two lead drug candidates.
• Increase in operational loss, explained notably by the contractual end of the R&D collaboration agreement with Novo Nordisk A/S.
• Cash position reinforced through the early refund of €10.4m in research tax credit; cash runway into 2011.

• Publication of important clinical data for IPH 1101 and IPH 2101, Innate Pharma’s two lead drug candidates.
• Increase in operational loss, explained notably by the contractual end of the R&D collaboration agreement with Novo Nordisk A/S.
• Cash position reinforced through the early refund of €10.4m in research tax credit; cash runway into 2011.

  Visit the investor section to download the interim financial report.